FIV Gag: virus assembly and host-cell interactions

Area of Science:

• Virology
• Molecular Biology
• Immunology

Background:

• Feline immunodeficiency virus (FIV) infection in cats mirrors human immunodeficiency virus type 1 (HIV-1) pathogenesis, making FIV a relevant model for anti-HIV therapies and vaccine development.
• FIV's inability to infect humans positions it as a potential non-toxic gene therapy vector.
• Understanding the cellular machinery used by FIV and HIV-1 for virus particle production is crucial for identifying therapeutic similarities.

Purpose of the Study:

• To review current knowledge on the interactions involving HIV-1 and FIV Gag proteins.
• To highlight the potential of FIV Gag as a novel antiviral target.
• To explore recent discoveries in intracellular restriction factors affecting lentiviral replication.

Main Methods:

• Literature review of studies on FIV and HIV-1 Gag protein functions.
• Analysis of viral assembly, release, and host cell machinery utilization.
• Examination of intracellular restriction factors impacting lentiviral capsids.

Main Results:

• FIV Gag protein interactions are increasingly understood, including targeting to the plasma membrane and virion assembly.
• The Gag precursor polyprotein is essential and self-sufficient for virus particle assembly and release.
• Novel research areas include intracellular restriction factors targeting lentiviral capsids post-entry.

Conclusions:

• The FIV model provides critical insights into lentiviral replication mechanisms relevant to HIV-1.
• Exploiting the FIV Gag gene offers potential for novel antiviral strategies beyond current therapies targeting pol and env genes.
• Further research into FIV-HIV-1 Gag interactions and restriction factors can advance antiviral drug and vaccine development.